In pre-clinical studies, for examples, a classic G9a inhibitor BIX-01294 induced autophagy-associated cell death and impaired tumor growth in breast cancer [145], oral squamous cell carcinoma [146] and hepatocellular carcinoma [[145], [146], [147]]; GSKJ4, the selective inhibitor of KDM6A and KDM6B, not only effectively suppressed tumor progression in AML [148], breast cancer [149], ovarian cancer [150] and castration-resistant prostate cancer [151], but also enhanced the radiosensitivity of multiple tumor cell lines [152]. The gene discussed is KDM6A; the disease is breast carcinoma.